Intravitreal bevacizumab for diabetic macular edema

Basit Öğe Kaydı
dc.contributor.authorAlakuş M.F.
dc.contributor.authorTaş M.
dc.contributor.authorÖner V.
dc.contributor.authorIşcan Y.
dc.contributor.authorTürkçü F.M.
dc.contributor.authorŞimşek A.
dc.contributor.authorÜnlü M.K.
dc.date.accessioned2024-04-24T18:43:42Z
dc.date.available2024-04-24T18:43:42Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose: To evaluate the effects of intravitreal bevacizumab administration on visual acuity (VA), intraocular pressure (IOP) and central foveal thickness (CFT) in patients with diabetic macular edema. Materials and Methods: İntravitreal bevacizumab injection was applied to 39 eyes of 35 patients that presented our clinic with diabetic macular edema, between December 2007 and December 2009. Before and 1 month after injection of 1,25 mg/ml bevacizumab VA,IOP and CFT was measured for each patient. On the second month,the second injection was applied to 29 eyes, and on the third month the third injection was applied to 12 eyes with persistent macular edema. Results: The mean VA increased from 0.206±0.17 to 0.294±22.1 month after first injection (p<0.05). The mean VA was 0.285±0.23 and 0.417±0.31 after second and third injections, respectively. The difference was statistically significant. The mean CMT was reduced from 464.5±115.35 to 332.11±127.60, 1 month after first injection (p<0.05). The mean CMT was 402.50±124.00 and 370.0±142.31 after second and third injections, respectively. The mean IOP was 13.11±2.80 mmHg before first injection, was 13.31±3.22, 13.72±3.04,14.27±2.72 mmHg after first, second and third injections respectively. Conclusion: There was significant difference between the mean IOPs after second and third injections.en_US
dc.identifier.endpage40en_US
dc.identifier.issn1300-1256
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-84862103589en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage35en_US
dc.identifier.urihttps://hdl.handle.net/11468/24314
dc.identifier.volume20en_US
dc.indekslendigikaynakScopus
dc.language.isotren_US
dc.relation.ispartofRetina-Vitreusen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBevacizumaben_US
dc.subjectDiabetic Macular Edemaen_US
dc.subjectIntravitreal İnjectionen_US
dc.titleIntravitreal bevacizumab for diabetic macular edemaen_US
dc.title.alternativeDiabetik maküla ödeminde intravitreal bevacizumab etkinliğininin değerlendirilmesien_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu